One-year access to more than 500 world journals available in the system
-
http://medilib.ir
- Duration of Time : 365 Day
Price : 300$- Special Price : 100$
Patient global assessment to define remission in rheumatoid arthritis:quo vadis?
Maarten Boers
doi : 10.1136/annrheumdis-2020-218802
Annals of the Rheumatic Diseases 2021;80:277-279.
Use of multidimensional composite scores in rheumatology: parsimony versus subtlety
Robert B M Landewé, Désirée van der Heijde
doi : 10.1136/annrheumdis-2020-216999
Annals of the Rheumatic Diseases 2021;80:280-285.
Rheumatic and musculoskeletal diseases (RMDs) form a diverse group of diseases. Proper disease assessment is pivotal, for instance to make treatment choices and for optimising outcome in general. RMDs are multidimensional diseases, entrenching many, sometimes very different aspects. Composite outcome measures (‘composites’) have become very popular to assess RMDs, because of their claim to catch all relevant dimensions of the disease into one convenient measure.
Burden and trajectory of multimorbidity in rheumatoid arthritis: a matched cohort study from 2006 to 2015
Bryant R England, Punyasha Roul, Yangyuna Yang, Harlan Sayles, Fang Yu, Kaleb Michaud, Fenglong Xie, Jeffrey R Curtis, Ted R Mikuls
doi : 10.1136/annrheumdis-2020-218282
Annals of the Rheumatic Diseases 2021;80:286-292
Objectives To compare the onset and trajectory of multimorbidity between individuals with and without rheumatoid arthritis (RA).
Revisiting the use of remission criteria for rheumatoid arthritis by excluding patient global assessment: an individual meta-analysis of 5792 patients
Ricardo J O Ferreira, Paco M J Welsing, Johannes W G Jacobs, Laure Gossec, Mwidimi Ndosi, Pedro M Machado, Désirée van der Heijde, Jose A P Da Silva
doi : 10.1136/annrheumdis-2020-217171
Annals of the Rheumatic Diseases 2021;80:293-303.
Objectives To determine the impact of excluding patient global assessment (PGA) from the American College of Rheumatology (ACR)/European League Against Rheumatism (EULAR) Boolean remission criteria, on prediction of radiographic and functional outcome of rheumatoid arthritis (RA).
Safety profile of upadacitinib in rheumatoid arthritis: integrated analysis from the SELECT phase III clinical programme
Stanley B Cohen, Ronald F van Vollenhoven, Kevin L Winthrop, Cristiano A F Zerbini, Yoshiya Tanaka, Louis Bessette, Ying Zhang, Nasser Khan, Barbara Hendrickson, Jeffrey V Enejosa, Gerd R Burmester
doi : 10.1136/annrheumdis-2020-218510
Annals of the Rheumatic Diseases 2021;80:304-311.
Objectives This integrated analysis presents the safety profile of upadacitinib, a Janus kinase inhibitor, at 15?mg and 30?mg once daily in patients with moderately to severely active rheumatoid arthritis (RA).
Upadacitinib for psoriatic arthritis refractory to biologics: SELECT-PsA 2
Philip J Mease, Apinya Lertratanakul, Jaclyn K Anderson, Kim Papp, Filip Van den Bosch, Shigeyoshi Tsuji, Eva Dokoupilova, Mauro Keiserman, Xin Wang, Sheng Zhong, Reva M McCaskill, Patrick Zueger, Aileen L Pangan, William Tillett
doi : 10.1136/annrheumdis-2020-218870
Annals of the Rheumatic Diseases 2021;80:312-320.
Background Upadacitinib is a Janus kinase inhibitor under evaluation for the treatment of psoriatic arthritis (PsA). We evaluated upadacitinib in patients with PsA and prior inadequate response or intolerance to at least one biologic disease-modifying antirheumatic drug (DMARD).
Combined genetic analysis of juvenile idiopathic arthritis clinical subtypes identifies novel risk loci, target genes and key regulatory mechanisms
Elena L?pez-Isac, Samantha L Smith, Miranda C Marion, Abigail Wood, Marc Sudman, Annie Yarwood, Chenfu Shi, Vasanthi Priyadarshini Gaddi, Paul Martin, Sampath Prahalad, Stephen Eyre, Gisela Orozco, Andrew P Morris, Carl D Langefeld, Susan D Thompson, Wendy Thomson, John Bowes
doi : 10.1136/annrheumdis-2020-218481
Annals of the Rheumatic Diseases 2021;80:321-328.
Objectives Juvenile idiopathic arthritis (JIA) is the most prevalent form of juvenile rheumatic disease. Our understanding of the genetic risk factors for this disease is limited due to low disease prevalence and extensive clinical heterogeneity. The objective of this research is to identify novel JIA susceptibility variants and link these variants to target genes, which is essential to facilitate the translation of genetic discoveries to clinical benefit.
Interleukin 6 receptor inhibition in primary Sj?gren syndrome: a multicentre double-blind randomised placebo-controlled trial
Renaud Felten, Valérie Devauchelle-Pensec, Raphaèle Seror, Pierre Duffau, David Saadoun, Eric Hachulla, Hatron Pierre Yves, Carine Salliot, Aleth Perdriger, Jacques Morel, Arsène Mékinian, Olivier Vittecoq, Jean-Marie Berthelot, Emanuelle Dernis, Veronique Le Guern, Philippe Dieudé, Claire Larroche, Christophe Richez, Thierry Martin, Charles Zarnitsky, Gilles Blaison, Pierre Kieffer, François Maurier, Azeddine Dellal, Stephanie Rist, Emmanuel Andres, Anne Contis, Emmanuel Chatelus, Christelle Sordet, Jean Sibilia, Cécile Arnold, Mira Y Tawk, Ouafaa Aberkane, Lise Holterbach, Patrice Cacoub, Alain Saraux, Xavier Mariette, Nicolas Meyer, Jacques-Eric Gottenberg
doi : 10.1136/annrheumdis-2020-218467
Annals of the Rheumatic Diseases 2021;80:329-338.
Objectives No immunomodulatory drug has been approved for primary Sj?gren’s syndrome, a systemic autoimmune disease affecting 0.1% of the population. To demonstrate the efficacy of targeting interleukin 6 receptor in patients with Sj?gren’s syndrome-related systemic complications.
Efficacy and safety of abatacept in active primary Sj?gren’s syndrome: results of a phase III, randomised, placebo-controlled trial
Alan N Baer, Jacques-Eric Gottenberg, E William St Clair, Takayuki Sumida, Tsutomu Takeuchi, Raphaèle Seror, Gary Foulks, Marleen Nys, Sumanta Mukherjee, Robert Wong, Neelanjana Ray, Hendrika Bootsma
doi : 10.1136/annrheumdis-2020-218599
Annals of the Rheumatic Diseases 2021;80:339-348.
Objectives To evaluate efficacy and safety of abatacept in adults with active primary Sj?gren’s syndrome (pSS) in a phase III, randomised, double-blind, placebo-controlled trial.
Efficacy of tocilizumab in patients with hand osteoarthritis: double blind, randomised, placebo-controlled, multicentre trial
Pascal Richette, Augustin Latourte, Jérémie Sellam, Daniel Wendling, Muriel Piperno, Philippe Goupille, Yves-Marie Pers, Florent Eymard, Sébastien Ottaviani, Paul Ornetti, René-Marc Flipo, Bruno Fautrel, Olivier Peyr, Jean Pierre Bertola, Eric Vicaut, Xavier Chevalier
doi : 10.1136/annrheumdis-2020-218547
Annals of the Rheumatic Diseases 2021;80:349-355.
Objective To evaluate the efficacy of tocilizumab, an antibody against IL-6 receptor, in patients with hand osteoarthritis.
Precise targeting of miR-141/200c cluster in chondrocytes attenuates osteoarthritis development
Ming-Liang Ji, Hua Jiang, Fei Wu, Rui Geng, Li kun Ya, Yu Cheng Lin, Ji Hao Xu, Xiao Tao Wu, Jun Lu
doi : 10.1136/annrheumdis-2020-218469
Annals of the Rheumatic Diseases 2021;80:356-366.
Objectives Despite preclinical studies involving miRNA therapeutics conducted in osteoarthritis (OA) over the years, none of these miRNAs have yet translated to clinical applications, owing largely to the lack of efficient intra-articular (IA) delivery systems. Here, we investigated therapeutic efficacy of the chondrocyte-specific aptamer-decorated PEGylated polyamidoamine nanoparticles (NPs)-based miRNAs delivery for OA.
Genome-wide association of phenotypes based on clustering patterns of hand osteoarthritis identify WNT9A as novel osteoarthritis gene
Cindy Germaine Boer, Michelle S Yau, Sarah J Rice, Rodrigo Coutinho de Almeida, Kathleen Cheung, Unnur Styrkarsdottir, Lorraine Southam, Linda Broer, Jeremy Mark Wilkinson, André G Uitterlinden, Eleftheria Zeggini, David Felson, John Loughlin, Mariel Young, Terence Dante Capellini, Ingrid Meulenbelt, Joyce BJ van Meurs
doi : 10.1136/annrheumdis-2020-217834
Annals of the Rheumatic Diseases 2021;80:367-375.
Background Despite recent advances in the understanding of the genetic architecture of osteoarthritis (OA), only two genetic loci have been identified for OA of the hand, in part explained by the complexity of the different hand joints and heterogeneity of OA pathology.
OATargets: a knowledge base of genes associated with osteoarthritis joint damage in animals
Jamie Soul, Matthew J Barter, Christopher B Little, David A Young
doi : 10.1136/annrheumdis-2020-218344
Annals of the Rheumatic Diseases 2021;80:376-383.
Objectives To collate the genes experimentally modulated in animal models of osteoarthritis (OA) and compare these data with OA transcriptomics data to identify potential therapeutic targets.
Prevalence and clinical outcomes of COVID-19 in patients with autoimmune diseases: a systematic review and meta-analysis
Shintaro Akiyama, Shadi Hamdeh, Dejan Micic, Atsushi Sakuraba
doi : 10.1136/annrheumdis-2020-218946
Annals of the Rheumatic Diseases 2021;80:384-391.
Objectives The prevalence and clinical outcomes of COVID-19 in patients with autoimmune diseases who are frequently treated with disease modifying therapies remains poorly understood. This meta-analysis aims to assess the prevalence and clinical outcomes of COVID-19 in autoimmune diseases.
High frequency of variants in genes associated with primary immunodeficiencies in patients with rheumatic diseases with secondary hypogammaglobulinaemia
Georgios Sogkas, Natalia Dubrowinskaja, Ignatius Ryan Adriawan, Manfred Anim, Torsten Witte, Reinhold E Schmidt, Faranaz Atschekzei
doi : 10.1136/annrheumdis-2020-218280
Annals of the Rheumatic Diseases 2021;80:392-399.
Objectives Treatment of rheumatic diseases requires immunomodulatory agents which can compromise antibody production. However, even in case of agents directly targeting B cells, a minority of patients develop hypogammaglobulinaemia, suggesting a genetic predisposition, which has not been investigated so far. The phenotypic overlap between primary immunodeficiency disorders (PIDs) and rheumatic diseases suggests a shared genetic basis, especially in case of patients with rheumatic diseases with hypogammaglobulinaemia.
COVID-19 and how evidence of a new disease evolves
Féline P B Kroon, Ted R Mikuls, Robert BM Landewé
doi : 10.1136/annrheumdis-2020-218483
Annals of the Rheumatic Diseases 2021;80:401-402
High oligoclonality of immunoglobulins in SARS-CoV2 positive patients
Marie Kolopp-Sarda, Pierre Miossec
doi : 10.1136/annrheumdis-2020-218316
Annals of the Rheumatic Diseases 2021;80:402-403.
Increased risk of systemic lupus erythematosus in patients with autoimmune haemolytic anaemia: a nationwide population-based cohort study
Han-You Mo, James Cheng Chung Wei, Xiao-Huan Chen, Hsin-Hua Chen
doi : 10.1136/annrheumdis-2020-218886
Annals of the Rheumatic Diseases 2021;80:403-404.
Toll-like receptors revisited; a possible role for TLR1 in lupus nephritis
Sule Yavuz, Matteo Bianchi, Sergey Kozyrev, Karin Bolin, Dag Leonard, Pascal Pucholt, Johanna K Sandling, Anders Bengtsson, Andreas J?nsen, Solbritt Rantap??-Dahlqvist, Christopher Sj?wall, Elisabet Svenungsson, Iva Gunnarsson, Kerstin Lindblad-Toh, Lars R?nnblom
doi : 10.1136/annrheumdis-2020-218373
Annals of the Rheumatic Diseases 2021;80:404-406.
Janus kinase (JAK) inhibition with baricitinib in refractory juvenile dermatomyositis
Hanna Kim, Samantha Dill, Michelle O'Brien, Laura Vian, Xiaobai Li, Manuk Manukyan, Minal Jain, Lilian W Adeojo, Jomy George, Maria Perez, Alexei A Grom, Michelle Sutter, Brian M Feldman, Lawrence Yao, Michelle Millwood, April Brundidge, Dominique C Pichard, Edward W Cowen, Yinghui Shi, Shajia Lu, Wanxia Li Tsai, Massimo Gadina, Lisa G Rider, Robert A Colbert
doi : 10.1136/annrheumdis-2020-218690
Annals of the Rheumatic Diseases 2021;80:406-408.
Antimalarial use and arrhythmias in COVID-19 and rheumatic patients: a matter of dose and inflammation?
Gian Luca Erre, Edoardo Sean Ferraccioli, Matteo Piga, Arduino Mangoni, Giuseppe Passiu, Elisa Gremese, Gianfranco Ferraccioli
doi : 10.1136/annrheumdis-2020-217828
Annals of the Rheumatic Diseases 2021;80:e29.
Response to: ‘Antimalarial use and arrhythmias in COVID-19 and rheumatic patients: a matter of dose and inflammation?’ by Erre et al
Elizabeth R Graef, Jean W Liew, Alfred HJ Kim, Jeffrey A Sparks
doi : 10.1136/annrheumdis-2020-217923
Annals of the Rheumatic Diseases 2021;80:e30.
Hydroxychloroquine shortages during the COVID-19 pandemic
Arielle Mendel, Sasha Bernatsky, J Carter Thorne, Diane Lacaille, Sindhu R Johnson, ?velyne Vinet
doi : 10.1136/annrheumdis-2020-217835
Annals of the Rheumatic Diseases 2021;80:e31.
Response to: ‘Hydroxychloroquine shortages during the COVID-19 pandemic’ by Mendel et al
Iain McInnes
doi : 10.1136/annrheumdis-2020-217954
Annals of the Rheumatic Diseases 2021;80:e32.
Correspondence on ‘Clinical course of coronavirus disease 2019 (COVID-19) in a series of 17 patients with systemic lupus under long-term treatment with hydroxychloroquine’
Mandana Nikpour, Benjamin Teh, Ian P Wicks, Marc Pellegrini
doi : 10.1136/annrheumdis-2020-217827
Annals of the Rheumatic Diseases 2021;80:e33.
Response to: ‘Correspondence on ‘Clinical course of coronavirus disease 2019 (COVID-19) in a series of 17 patients with systemic lupus under long-term treatment with hydroxychloroquine’’ by Nikpour et al
Alexis Mathian, Zahir Amoura
doi : 10.1136/annrheumdis-2020-217875
Annals of the Rheumatic Diseases 2021;80:e34.
Patients with lupus with COVID-19: University of Michigan experience
Beth Wallace, Laraine Washer, Wendy Marder, J Michelle Kahlenberg
doi : 10.1136/annrheumdis-2020-217794
Annals of the Rheumatic Diseases 2021;80:e35.
Response to: ‘Patients with lupus with COVID-19: University of Michigan experience’ by Wallace et al
Alexis Mathian, Zahir Amoura
doi : 10.1136/annrheumdis-2020-217910
Annals of the Rheumatic Diseases 2021;80:e36
Severe COVID-19-associated pneumonia in 3 patients with systemic sclerosis treated with rituximab
Jérôme Avouac, Paolo Air?, Nicolas Carlier, Marco Matucci-Cerinic, Yannick Allanore
doi : 10.1136/annrheumdis-2020-217864
Annals of the Rheumatic Diseases 2021;80:e37.
Response to: ‘Severe COVID-19 associated pneumonia in 3 patients with systemic sclerosis treated with rituximab’ by Avouac et al
Philippe Guilpain, Clément Le Bihan, Vincent Foulongne, Patrice Taourel, Nathalie Pansu, Alexandre Thibault Jacques Maria, Boris Jung, Romaric Larcher, Kada Klouche, Vincent Le Moing
doi : 10.1136/annrheumdis-2020-217955
Annals of the Rheumatic Diseases 2021;80:e38.
COVID-19 infection in a patient with FMF: does colchicine have a protective effect?
Senol Kobak
doi : 10.1136/annrheumdis-2020-217882
Annals of the Rheumatic Diseases 2021;80:e39.
Candidate rheumatologic treatments for COVID-19. Response to: ‘COVID-19 infection in a patient with FMF: does colchicine have a protective effect?’ by Kobak
Sara Monti, Carlomaurizio Montecucco
doi : 10.1136/annrheumdis-2020-217957
Annals of the Rheumatic Diseases 2021;80:e40.
COVID-19 and Behçet’s disease: clinical case series
Gerard Espinosa, Olga Araujo, Sergi Amaro, Marta Bodro, Pedro Juan Moreno, Reinaldo Moreno, Ainoa Ugarte, R Cervera
doi : 10.1136/annrheumdis-2020-217778
Annals of the Rheumatic Diseases 2021;80:e41
Myositis as a manifestation of SARS-CoV-2
Maxime Beydon, Kevin Chevalier, Omar Al Tabaa, Sabrina Hamroun, Anne-Sophie Delettre, Marion Thomas, Julia Herrou, Elodie Riviere, Xavier Mariette
doi : 10.1136/annrheumdis-2020-217573
Annals of the Rheumatic Diseases 2021;80:e42.
Rheumatic disease and COVID-19
Jean W Liew, Elizabeth R Graef
doi : 10.1136/annrheumdis-2020-217674
Annals of the Rheumatic Diseases 2021;80:e43.
COVID-19 in rheumatology outpatient clinics: Dutch mirror image to Lombardy, Italy
Sophie Benoy, Rene Traksel, Peter Verhaegh, Jasper Broen
doi : 10.1136/annrheumdis-2020-217765
Annals of the Rheumatic Diseases 2021;80:e44
Correction: Pragmatic randomised controlled trial of very early etanercept and MTX versus MTX with delayed etanercept in RA: the VEDERA trial
doi : 10.1136/annrheumdis-2019-216539corr1
Annals of the Rheumatic Diseases 2021;80:e45
